|
AP1019A
(en)
|
1996-10-18 |
2001-10-16 |
Vertex Pharma |
Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
|
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
|
UY28500A1
(es)
|
2003-09-05 |
2005-04-29 |
Vertex Pharma |
Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
|
|
CN102206216B
(zh)
*
|
2005-06-22 |
2014-11-12 |
普莱希科公司 |
作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
|
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
|
AU2007217355B2
(en)
|
2006-02-27 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
|
|
WO2007109080A2
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP2674428B1
(en)
|
2006-04-07 |
2016-04-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
WO2008106058A2
(en)
|
2007-02-27 |
2008-09-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
|
HRP20120330T1
(hr)
|
2007-02-27 |
2012-05-31 |
Vertex Pharmaceuticals Incorporated |
Sukristali i farmaceutski pripravci koji ih sadrže
|
|
JP2010533729A
(ja)
|
2007-07-17 |
2010-10-28 |
プレキシコン，インコーポレーテッド |
キナーゼ調節のための化合物と方法、及びそのための適応
|
|
NZ583699A
(en)
|
2007-08-30 |
2012-04-27 |
Vertex Pharma |
Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
|
|
CA2717326C
(en)
*
|
2008-03-11 |
2018-10-23 |
Dr. Reddy's Laboratories Ltd. |
Preparation of lenalidomide
|
|
MX2010010050A
(es)
|
2008-03-20 |
2011-03-15 |
Virun Inc Star |
Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
|
|
WO2009117151A2
(en)
|
2008-03-20 |
2009-09-24 |
Virun, Inc. |
Compositions containing non-polar compounds
|
|
JP2011522862A
(ja)
*
|
2008-06-10 |
2011-08-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
|
|
GB0815852D0
(en)
|
2008-09-01 |
2008-10-08 |
Unilever Plc |
Improvements relating to pharmaceutical compositions
|
|
CA2737481A1
(en)
*
|
2008-09-16 |
2010-03-25 |
Douglas Ludtke |
Stable solid oral dosage co-formulations
|
|
WO2010093843A2
(en)
|
2009-02-12 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Hcv combination therapies
|
|
KR101739994B1
(ko)
|
2009-04-03 |
2017-05-25 |
에프. 호프만-라 로슈 아게 |
프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
|
|
TW201043269A
(en)
*
|
2009-04-14 |
2010-12-16 |
Bristol Myers Squibb Co |
Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
|
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
NZ599866A
(en)
|
2009-11-06 |
2014-09-26 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
AU2011210795A1
(en)
|
2010-01-29 |
2012-08-02 |
Vertex Pharmaceuticals Incorporated |
Therapies for treating Hepatitis C virus infection
|
|
CN103037708B
(zh)
|
2010-03-23 |
2015-05-20 |
维尔恩公司 |
含有蔗糖脂肪酸酯的纳米乳液
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
SI2826776T1
(sl)
*
|
2010-03-25 |
2021-02-26 |
Vertex Pharmaceuticals Incorporated |
Trdna disperzija amorfne oblike (R)-1(2,2-difluorobenzo(D)(1,3)dioksol-5-il)-N-(1-(2,3-dihidroksipropil) -6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1H-indol-5-il)- ciklopropankarboksamida
|
|
MX353408B
(es)
|
2010-04-22 |
2018-01-11 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
|
US20130137739A1
(en)
*
|
2010-05-31 |
2013-05-30 |
Astellas Pharma, Inc. |
Solid dispersion comprising triazole compound
|
|
WO2011162802A1
(en)
|
2010-06-21 |
2011-12-29 |
Virun, Inc. |
Compositions containing non-polar compounds
|
|
US20170087134A1
(en)
*
|
2010-07-12 |
2017-03-30 |
Salix Pharmaceuticals, Ltd |
Formulations of rifaximin and uses thereof
|
|
EP2593105A1
(en)
|
2010-07-14 |
2013-05-22 |
Vertex Pharmaceuticals Incorporated |
Palatable pharmaceutical composition comprising vx-950
|
|
WO2012054870A2
(en)
|
2010-10-21 |
2012-04-26 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
|
KR101911972B1
(ko)
|
2011-02-07 |
2018-10-25 |
플렉시콘 인코퍼레이티드 |
키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
|
|
WO2012109646A1
(en)
|
2011-02-11 |
2012-08-16 |
Vertex Pharmaceuticals Incorporated |
Treatment of hcv in hiv infection patients
|
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
|
CA2829768A1
(en)
|
2011-03-18 |
2012-09-27 |
Abbvie Inc. |
Formulations of phenyl uracil compounds
|
|
MX2014000253A
(es)
*
|
2011-07-07 |
2014-10-17 |
Arqule Inc |
Formulaciones de pirroloquinolinil-pirrolidin-2,5-diona y metodos para preparar y utilizar las mismas.
|
|
EP2578974A1
(en)
|
2011-10-05 |
2013-04-10 |
Sanofi Pasteur Sa |
Process line for the production of freeze-dried particles
|
|
SE1450131A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE112012002748T5
(de)
|
2011-10-21 |
2014-07-31 |
Abbvie Inc. |
Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
|
|
US9034832B2
(en)
|
2011-12-29 |
2015-05-19 |
Abbvie Inc. |
Solid compositions
|
|
HK1201186A1
(en)
*
|
2011-12-29 |
2015-08-28 |
Abbvie Inc. |
Solid compositions comprising an hcv inhibitor
|
|
US20130195797A1
(en)
|
2012-01-31 |
2013-08-01 |
Vertex Pharmaceuticals Incorporated |
High potency formulations of vx-950
|
|
EP2811847B1
(en)
|
2012-02-10 |
2017-12-13 |
Virun, Inc. |
Beverage compositions containing non-polar compounds
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
JO3754B1
(ar)
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
|
WO2014015217A1
(en)
|
2012-07-19 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Biomarkers for hcv infected patients
|
|
WO2014096343A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Sandoz Ag |
Novel forms of telaprevir
|
|
PT2950786T
(pt)
|
2013-01-31 |
2020-03-03 |
Gilead Pharmasset Llc |
Formulação de combinação de dois compostos antivirais
|
|
CA2903831A1
(en)
|
2013-03-15 |
2014-09-25 |
Boehringer Ingelheim International Gmbh |
Solid oral dosage formulation of hcv inhibitor in the amorphous state
|
|
US9351517B2
(en)
|
2013-03-15 |
2016-05-31 |
Virun, Inc. |
Formulations of water-soluble derivatives of vitamin E and compositions containing same
|
|
EA201690473A1
(ru)
|
2013-08-27 |
2017-03-31 |
ГАЙЛИД ФАРМАССЕТ ЭлЭлСи |
Комбинированный состав двух противовирусных соединений
|
|
US20150182457A1
(en)
*
|
2013-12-31 |
2015-07-02 |
Ascendia Pharmaceuticals, Llc |
Pharmaceutical Compositions For Poorly Water-Soluble Compounds
|
|
RU2744460C2
(ru)
|
2014-04-15 |
2021-03-09 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
|
|
SG11201700849XA
(en)
*
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
|
US9861611B2
(en)
|
2014-09-18 |
2018-01-09 |
Virun, Inc. |
Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
CN106620711B
(zh)
*
|
2015-11-03 |
2019-06-25 |
中国科学院大连化学物理研究所 |
一种含有白藜芦醇的组合物及其制备方法
|
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
|
WO2017196712A1
(en)
*
|
2016-05-09 |
2017-11-16 |
Dispersol Technologies, Llc |
Improved drug formulations
|
|
PT3518924T
(pt)
|
2016-09-30 |
2022-10-27 |
Salix Pharmaceuticals Inc |
Formas de dispersão sólidas de rifaximina
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
WO2019134971A1
(en)
*
|
2018-01-04 |
2019-07-11 |
Sandoz Ag |
Encapsulated particles comprising a pharmaceutically active ingredient
|
|
EP3936127B1
(en)
*
|
2019-03-04 |
2025-04-30 |
Japan Tobacco Inc. |
Amorphous solid dispersion of pyrazole-amide compound
|
|
IL320609A
(en)
*
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|